Double C-Loop Haptic Lenses Are Rotationally Stable - A Systematic Review
- PMID: 40671883
- PMCID: PMC12266054
- DOI: 10.2147/OPTH.S536114
Double C-Loop Haptic Lenses Are Rotationally Stable - A Systematic Review
Abstract
The purpose of this review is to summarize the clinical rotational stability outcomes reported in patients following implantation of the POD platform with double C-loop haptics. A literature search in PubMed (US National Library of Medicine) was carried out to find publications, both prospective and retrospective, which report rotational stability outcomes in patients who were implanted with this platform after cataract or refractive lens exchange surgeries. This platform is used in different commercially available intraocular lenses (IOLs), both monofocal and trifocal, made of hydrophilic or hydrophobic material. 19 clinical peer-reviewed studies published between 2013 and 2024 were included in this review. The data reported in the clinical publications was analyzed in detail, focusing on rotational stability (mean rotation values and ranges, and percentage of eyes with some degrees of rotation), measurement methods and rotation follow-up period. Our review encompassed a total of 1428 eyes implanted with the POD platform analyzed at different follow-up periods, up to a maximum of 26 months. The mean rotation across all the studies was 2.61 °.The analysis carried out in this review leads us to conclude that the POD platform provides good rotational stability when used with different IOL models based on monofocal or trifocal designs and made using hydrophilic or hydrophobic material.
Keywords: double C-loop; haptic; intraocular lens; platform; rotational stability.
© 2025 Daya et al.
Conflict of interest statement
Sheraz Daya reports grant support from Allotex and Johnson & Johnson Vision; consultant/advisor of, lecture fees, and grant support from Bausch + Lomb; consultant/advisor of and lecture fees from BVI–Physiol; consultant/advisor of Cristalens, Carl Zeiss Meditec, Nidek, Inc., Oyster Point, Tarsus, and Vialase; consultant/advisor of, stock options, grant support from Excellens; owner of company of Infinite Medical Ventures (EO); consultant/advisor for and stock options from PRN. Christophe Chassain receives royalties by the company BVI–Physiol concerning PODEYE IOLs. Christophe Pagnoulle has a proprietary interest in the GF material. Dr. Pagnoulle is an employee of BVI Medical. Dr Christophe Pagnoulle has a patent US8636796B2 issued to Physiol SA, a patent BE1016383A3 issued to Physiol SA. The authors report no other conflicts of interest in this work.
Figures
References
Publication types
LinkOut - more resources
Full Text Sources
